Immunogenicity as a predictive tool for the response to therapy of high mutation load tumors (IMPRESS)

Project: PN-III-P4-ID-PCE-2016-0870

Specific Objectives

 

a) To evaluate molecules from each of the seven steps of the Cancer-Immunity Cycle  for which there is some evidence pointing towards a potential predictive role 
b) To evaluate the expression of the most important checkpoint molecules (PD-1/PD-L1) and their dynamics during therapy
c) To identify the potential of standard treatment modalities, such as RT, to activate an immune response
d) To evaluate some clinico-pathologic biomarkers which were showed to be important for the clinical outcome in these cancers and correlate them with the patient immune status and clinical response